The UK's National Institute for Health and Clinical Excellence (NICE) has rejected Avastin (bevacizumab) as a treatment for advanced bowel cancer, citing trial data that they say is both unconvincing and fails to justify cost.
Avastin's maker, Roche, had offered to supply the drug to the UK at a cost of £20,800 ($32,430) per patient for one year, after which the drug would be free. Roche had also agreed to reimburse NICE for the additional costs of chemotherapy treatment involving Oxaliplatin. Finally, Roche offered a per-patient payment to NICE up front for each patient who was started on Avastin as first-line therapy.
Despite these efforts to sweeten the deal, NICE still said no.
CANCER TYPE(S)
Colorectal cancer
TREATMENT TYPE(S)
Anti-angiogenesis
By Ross Bonander
Source
Fiercepharma
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
